New drug cocktail aims to stop smoldering myeloma in its tracks

NCT ID NCT06100237

Recruiting now Disease control Sponsor: Carl Ola Landgren, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining teclistamab or talquetamab with daratumumab can delay the onset of multiple myeloma in 50 people with high-risk smoldering myeloma. The goal is to achieve no detectable cancer cells after 12 cycles of treatment. Researchers will also monitor side effects to assess safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teclistamab or Talquetamab combined with Daratumumab
What this could lead to: If successful, this could delay or prevent the progression from smoldering myeloma to active multiple myeloma, potentially keeping patients disease-free for longer.
What could go wrong: This is an early phase 2 trial with only 50 participants, so results may not apply broadly. The drugs can cause serious side effects, and it's unknown if the benefit will last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

smoldering plasma cell myeloma plasma cell myeloma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.